

# CURRICULUM VITAE

**Kevin L. Sloan, M.D.**

**August, 2009**

## **EDUCATION:**

- 1982 Oberlin College, Oberlin, OH  
*AB magna cum laude*, Chemistry and Mathematics
- 1986 University of Chicago Pritzker School of Medicine, Chicago, IL  
MD

## **POSTGRADUATE TRAINING:**

- 1986–1987 Internship in Internal Medicine at Michael Reese Hospital,  
University of Chicago Pritzker School of Medicine, Chicago, IL
- 1987–1990 Residency in General Psychiatry,  
University of Chicago Pritzker School of Medicine, Chicago, IL

## **FACULTY POSITIONS HELD:**

- 1/1992–6/1995 Acting Instructor, Department of Psychiatry and Behavioral Sciences,  
University of Washington School of Medicine
- 7/1995–6/1998 Acting Assistant Professor, Department of Psychiatry and Behavioral  
Sciences, University of Washington School of Medicine
- 7/1998–6/2004 Assistant Professor, Department of Psychiatry and Behavioral Sciences,  
University of Washington School of Medicine
- 7/2004–7/2009 Associate Professor, Department of Psychiatry and Behavioral Sciences,  
University of Washington School of Medicine

## **POSITIONS HELD:**

- 1989 Junior Attending Physician, W-3 Inpatient Unit, Department of  
Psychiatry, University of Chicago, Chicago, IL
- 7/1990–12/1991 Director, Psychiatric Acute Care Unit, Department of Psychiatry, Albert  
Einstein Medical Center, Northern Division, Philadelphia, PA
- 1/1992–5/2009 Chief, Dual Disorders Program, Addictions Treatment Center, Mental  
Health Service, VA Puget Sound Health Care System—Seattle Division,  
Seattle, WA
- 6/2009–present Private Practice of Psychiatry, Mercer Island, WA

## **HONORS:**

- 1978–1982 Ohio Academic Scholarship
- 1978–1982 Gardner Scholarship
- 1981 American Chemical Society Analytical Chemistry Award
- 1981 Michael Reese Hospital Research Training Fellowship
- 1982 finalist Winston Churchill Scholarship
- 1982 Harry N. Holmes Prize in Chemistry
- 1982 Sigma Xi Research Society
- 1982 Phi Beta Kappa

## **CURRICULUM VITAE**

**Kevin L. Sloan, M.D.**

**Page 2 of 11**

- 2002 Department of Veterans Affairs (VISN 20) Special Contribution Award for Hepatitis C risk analysis
- 2004 Department of Veterans Affairs Public Health Strategic Health Care Group Special Contribution Award (Hepatitis C)

### **BOARD CERTIFICATION:**

- 1987 National Board of Medical Examiners
- 1992 American Board of Psychiatry and Neurology – Psychiatry
- 1994, 2004 American Board of Psychiatry and Neurology – Added Qualifications in Addiction Psychiatry

### **LICENSURE TO PRACTICE:**

- 1987–1990 State of Illinois
- 1990–1992 Commonwealth of Pennsylvania
- 1992–present State of Washington

### **PROFESSIONAL ORGANIZATIONS – CURRENT:**

- American Psychiatric Association
- Washington State Psychiatric Association

### **PROFESSIONAL ORGANIZATIONS – PREVIOUS:**

- AcademyHealth (formerly the Academy for Health Services Research and Health Policy)
- American Statistical Association
- International Health Economics Association

### **TEACHING RESPONSIBILITIES:**

#### *Courses & seminars:*

- 1992–1999 Supervisor, ICM-II – The Psychiatric Interview
- 1992, 1995 Preceptor, Advanced Clinical Seminar in Substance Use Disorders II (Department of Psychosocial Nursing PSN 558)
- 1993–1995 Co-coordinator, VA Center of Excellence in Substance Abuse Treatment and Education (CESATE) Interdisciplinary Fellowship Seminar
- 1996–2007 Lecturer, Psychiatric Assessment and Treatment, VA Center of Excellence in Substance Abuse Treatment and Education (CESATE) Interdisciplinary Fellowship Seminar
- 1996–2000 Lecturer, R-2 Substance Disorders Module
- 1997–2001 Preceptor, Nursing Research Training, Substance Abuse.

#### *Training Workshops:*

- 5/1994 Organizer and co-presenter, “Assessment and Treatment of the Dually Disordered Patient”, full-day workshop, Willapa Counseling Center, Pacific County, WA.

## **CURRICULUM VITAE**

**Kevin L. Sloan, M.D.**

**Page 3 of 11**

- 9/1996 Sole presenter, "Assessment and Treatment of the Dually Disordered Patient", full-day workshop, Sheridan VA Medical Center.
- 2/1997 Co-presenter, "Merging Science and Practice in Substance Abuse Treatment", VA Mental Health Strategic Health Care Group, full-day workshop, Washington DC.
- 8/1997 Sole presenter, "Assessment and Treatment of the Dually Disordered Patient", full-day training workshop, Spokane VA Medical Center.
- 9/1998 Sole presenter, "Dual Diagnosis: Assessment, Treatment and Suicide", full-day workshop, White City VA Medical Center.
- 12/1999 Sole presenter, "Issues in Dual Diagnosis Assessment and Treatment", half-day workshop, University of Washington School of Public Affairs.
- 5/2000 Sole presenter, "Bridging the Gap: Assessment and Treatment of the Dually Disordered Patient", full-day workshop, Portland VA Medical Center.

### **EDITORIAL RESPONSIBILITIES:**

Ad hoc reviewer: Medical Care, American Journal of Public Health, and Psychiatric Services

### **NATIONAL RESPONSIBILITIES:**

- 1999–2004 Investigator, VA Mental Health Quality Enhancement Research Initiative (QUERI)
- 1999–2004 Investigator, VA Ischemic Heart Disease Quality Enhancement Research Initiative (QUERI)
- 1999–2004 Affiliate Investigator, Northwest Health Services Research and Development Center of Excellence
- 2002–2007 Core Staff Investigator, VA Northwest Hepatitis C Resource Center
- 2003–2007 Core Investigator, Seattle Center for Excellence for Substance Abuse, Treatment and Education
- 2003–2007 Core Investigator, Seattle Epidemiologic Research and Information Center
- 2004–2007 Core Investigator, Northwest Health Services Research and Development Center of Excellence
- 2004–2007 Advisory Board Member, VA Multiple Sclerosis Center of Excellence (West)

### **LOCAL AND REGIONAL RESPONSIBILITIES:**

- 1988–1990 Committee on Research in Psychoanalysis, Chicago Psychoanalytic Institute, Chicago, IL
- 1989 Outpatient Administrative Committee, Department of Psychiatry, University of Chicago, Chicago, IL
- 1993–1997 VA Puget Sound Health Care System Addictions Treatment Center, QA Committee

## CURRICULUM VITAE

Kevin L. Sloan, M.D.

Page 4 of 11

1993–2004	VA Puget Sound Health Care System, Death and Suicide Review Committee
1993–2007	VA Puget Sound Health Care System Addictions Treatment Center, Administrative Committee
1994–2007	VA Puget Sound Health Care System Addictions Treatment Center, Addictions Psychiatry Residency Steering Committee
1996–1997	Director, VA Puget Sound Health Care System Addictions Treatment Center, Addictions Psychiatry Residency
1997–2004	Staff Consultant, VA VISN 20 Consumer Health Information and Performance Set (CHIPS) project, (10% effort)
1998–2004	VA Puget Sound Health Care System Narcotics Medication Review Board
1999–2001	Ad hoc member, Small Grants Review Committee, Alcohol and Drug Abuse Institute, University of Washington
1999–2007	VA Puget Sound Health Care System, Health Services Research and Development Research Review Committee

### RESEARCH FUNDING:

1. PI: Calsyn DA, co-PI: **Sloan KL**: Comparison of two attrition prevention interventions in patients with comorbid substance dependence and major psychiatric illness. University of Washington Alcohol and Drug Abuse Institute. 65-0108 (Calsyn), 7/94–7/96, 10% effort, \$15,000.
2. PI: Donovan DM, co-PI: Cox GB: Attrition while awaiting drug treatment. National Institute on Drug Abuse, 5% effort, \$1,616,322.
3. PI: Saxon AJ, co-PI: **Sloan KL**: Safety of disulfiram (Antabuse) for alcohol dependent patients with hepatitis C infection and/or abnormal liver function tests. University of Washington Alcohol and Drug Abuse Institute. 65-0108 (Saxon), 7/94–7/96, 5% effort, \$15,000.
4. PI: Sales AE, co-PI: Every NR: Lipid Measurement and Management System. VHA Health Services Research and Development Service (SDR). 4/99–2/00, 10% effort, \$487,505.
5. PI: Owen R: Documentation of Major Depressive Disorder and Schizophrenia-Related Performance Criteria. VHA Health Services Research and Development Service, 10% effort, \$28,926 (Seattle site).
6. PI: Sales AE, co-PI **Sloan KL**: Modification of the Chronic Disease Score for a VA Population. VHA Health Services Research and Development Service. 1/00–9/01, 15% effort, \$135,442.
7. PI: Johnson MJ, site PI **Sloan KL**: Hypertension, Diabetes, Hyperlipidemia Treatment and Outcomes: A Regional Study of Patients in the VA. Pfizer. 2/02–2/03. 5% effort. \$217,000.
8. PI: Saxon AJ: On-site vs. Referral Models of Primary Care for Substance Abusing Patients. VHA Health Services Research and Development Service. 10/99–3/04, 5% effort, \$940,455.
9. PI: Rosen AK: Development and Application of a psychiatric case-mix measure for the VA. VHA Health Services Research and Development Service. 4/01–3/04. 10% effort, \$625,900.

## CURRICULUM VITAE

Kevin L. Sloan, M.D.

Page 5 of 11

10. PI: **Sloan KL**: Effects of Outlier Identification Strategy on Facility Profiling. VHA Health Services Research and Development Service. 10/02–9/05. 30% effort, \$745,029.
11. PI: Madaras-Kelly KJ. Etiology, Epidemiology, and Clinical Outcomes of Health Care Associated Pneumonia. 06/08–05/10. 8% effort, \$61,996.

## BIBLIOGRAPHY

### MANUSCRIPTS IN REFEREED JOURNALS:

1. Craig NC, **Sloan KL**, Sprague JR and Stevens PS: 3-Fluorocyclopropene. *J Org Chem* 49:3847–48, 1984.
2. **Sloan KL** and Rowe G: Substance abuse and psychiatric illness: Psychosocial correlates. *Am J Addiction* 4:60–69, 1995.
3. Howard MO, McGuffin RW, Saxon AJ, **Sloan KL** and Walker RD: Clinical issues related to the costs of alcoholism. *Pharmacoeconomics* 9:134–145, 1996.
4. Saxon AJ, **Sloan KL**, Reoux J and Haver VL: Disulfiram use in patients with abnormal liver function test results. *J Clin Psychiatry* 59(6):313–316, 1998.
5. **Sloan KL** and Rowe G: Substance Abuse and Psychiatric Illness: Treatment Experience. *Am J Drug Alcohol Abuse*, 24(4):589–601, 1998.
6. **Sloan KL**, Kivlahan D and Saxon AJ: Detecting bipolar disorder among treatment-seeking substance abusers. *Am J Drug Alcohol Abuse* 26(1):13–23, 2000.
7. Saxon AJ, Davis TM, **Sloan KL**, McKnight KM, McFall ME, and Kivlahan DR: Trauma, symptoms of posttraumatic stress disorder, and associated problems among incarcerated veterans. *Psychiatric Serv* 52(7): 959–964, 2001.
8. Donovan DM, Rosengren DB, Downey L, Cox GB and **Sloan KL**: Attrition prevention with individuals awaiting publicly funded drug treatment. *Addiction* 96(8):1149–1160, 2001.
9. Reoux J, Malte C, Saxon A, **Sloan KL** and Baer J: Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. *Alc Clin Exp Res* 25(9):1324–1329, 2001.
10. **Sloan KL**, Sales AE, Willems JP, Every NR, Martin GV, Sun H, and Pineros S: Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results  $\leq$  100 mg/dl among patients who had coronary events (Northwest VA Network Study). *Am J Cardiol* 88(10):1143–6, 2001.
11. Felker B, **Sloan KL**, Barnes R, Dominitz JA: The safety of valproic acid use in patients with hepatitis C infection. *Am J Psychiatry* 160(1):174–8, 2003.
12. Ho PM, Maynard C, Starks H, Sun H, **Sloan K**, Sales A. Adverse Outcomes in IHD Patients Who Do Not Undergo Lipid Testing. *Am J Cardiol* 91(8):986–8, 2003.
13. Sales AE, Liu CF, **Sloan KL**, Malkin J, Fishman P, Rosen A, Loveland S, Nichol P, Suzuki NT, Perrin E, Sharp ND, Todd-Stenberg J: Predicting costs of care using a pharmacy-based measure: Risk adjustment in a veteran population. *Med Care* 41:753–760, 2003.

## CURRICULUM VITAE

**Kevin L. Sloan, M.D.**

**Page 6 of 11**

14. **Sloan KL**, Sales AE, Liu CF, Fishman P, Nichol P, Suzuki NT, Sharp ND: Construction and characteristics of the RxRisk-V: A VA-adapted pharmacy-based case-mix instrument. *Med Care* 41:761–774, 2003.
15. Calsyn DA, DeMarco FJ, Saxon AJ, **Sloan KL** and Gibbon KE: Evaluation of a Minimal Services Treatment Track for Noncompliant Patients in Opioid Substitution Treatment. *Am J Public Health* 93:1086–1088, 2003.
16. Straits-Tröster KA, **Sloan KL**, and Dominitz JA: Psychiatric and Substance Use Disorder Comorbidity with Hepatitis C. *Psychiatric Annals* 33(6):362–366, 2003.
17. Saxon AJ, Baer JS, Davis TM, **Sloan KL**, Malte CA, Fitzgibbons K, Kivlahan DR: Smoking cessation treatment among dually diagnosed individuals: preliminary evaluation of different pharmacotherapies. *Nicotine Tob Res* 5(4):589–96, 2003.
18. Kramer TL, Owen RR, Cannon D, **Sloan KL**, Thrush CR, Williams DK, Austen MA: How well do automated performance measures assess guideline implementation for new-onset depression in the Veterans Health Administration? *Jt Comm J Qual Saf* 29(9):479–89, 2003.
19. Liu CF, Sales AE, Sharp ND, Fishman P, **Sloan KL**, Todd-Stenberg J, Nichol WP, Rosen AK, Loveland S: Case-mix adjusting performance measures in a veteran population: pharmacy- and diagnosis-based approaches. *Health Serv Res* 38(5):1319–37, 2003.
20. Shores MM, **Sloan KL**, Matsumoto AM, Mocerri VM, Felker B, Kivlahan DR: Increased incidence of diagnosed depressive illness in hypogonadal older men. *Arch Gen Psychiatry* 61(2):162–7, 2004.
21. **Sloan KL**, Straits-Tröster KA, Dominitz JA, and Kivlahan DR: Hepatitis C Tested Prevalence and Comorbidities Among Veterans in the U.S. Northwest. *J Clin Gastroenterology* 38(3):279–284, 2004.
22. Owen RR, Thrush CR, Cannon D, **Sloan KL**, Curran G, Hudson T, Austen M, Ritchie M: Use of electronic medical record data for quality improvement in schizophrenia treatment. *J Am Med Inform Assoc* 11:351–357, 2004.
23. Calsyn DA, Saxon AJ, Bush KR, Howell DN, Baer JS, **Sloan KL**, Malte CA and Kivlahan DR. The Addiction Severity Index Medical and Psychiatric Composite Scores Measure Similar Domains as the SF-36V in Substance Dependent Veterans: Concurrent and Discriminant Validity. *Drug Alcohol Depend*: 76(2):165–71, 2004.
24. Chapko MK, **Sloan KL**, Davison J, Dufour DR, Bankson DD, Rigsby M, Dominitz JA. Cost effectiveness of testing strategies for chronic hepatitis C. *Am J Gastroenterology*: 100:607–615, 2005.
25. Maynard C, Kivlahan D, **Sloan KL**, Krupski A, Saxon A, Stark K: Utilization Of Department Of Veterans Affairs Health Care Services By Veterans Receiving Addiction Treatment In Washington State. *Psychological Serv*: 1:120-125.
26. Shores MM, Mocerri VM, **Sloan KL**, Matsumoto AM, Kivlahan DR. Low testosterone predicts incident depressive illness in older men: Effects of age and medical morbidity. *J Clin Psychiatry*: 66(1):7–14, 2005.

## **CURRICULUM VITAE**

**Kevin L. Sloan, M.D.**

**Page 7 of 11**

27. Saxon AJ, Malte CA, **Sloan KL**, Baer JS, Calsyn DA, Nichol P, Chapko MK, Kivlahan DR. Randomized Trial of Onsite vs. Referral Primary Medical Care for Veterans in Addictions Treatment. *Med Care*. 44(4):334-42; 2006.
28. Shores MM, Matsumoto AM, **Sloan KL**, Kivlahan DR. Low serum testosterone and mortality in male veterans. *Arch Intern Med*. 166(15):1660-5. Aug 14-28 2006.
29. **Sloan KL**, Montez ME, Spiro A, Christiansen CL, Loveland S, Shokeen P, Herz L, Eisen S, Breckenridge JN, Rosen AK. Development and Validation of a Psychiatric Case-Mix System. *Med Care*. 44(6):568-80; 2006.
30. Davison JW, Sweeney ML, Bush KR, Davis TM, Calsyn DA, Reoux JP, **Sloan KL**, Kivlahan DR: Outpatient treatment engagement and abstinence rates following inpatient opioid detoxification. *J Addict Dis*. 25(4):27-35, 2006.
31. Rosen AK, Christiansen CL, Montez ME, Loveland S, Shokeen P, **Sloan KL**, Ettner SL. Evaluating Risk-Adjustment Methodologies for Patients with Mental Health and Substance Abuse Disorders in the Veterans Health Administration. *International Journal of Healthcare Technology and Management*. 7(1/2):43-81. 2006.
32. Rousseau CM, Ioannou GN, Todd-Stenberg JA, **Sloan KL**, Larson MF, Forsberg CW, Dominitz JA. Racial differences in the evaluation and treatment of hepatitis C among veterans: a retrospective cohort study. *Am J Public Health*. 98(5):846-52, May 2008.
33. Madaras-Kelly KJ, Remington RE, Oliphant CM, **Sloan KL**, Bearden DT. Efficacy of oral beta-lactam versus non-beta-lactam treatment of uncomplicated cellulitis. *Am J Med*. 121(5):419-25. May 2008.
34. Chatterjee S, Rath ME, Spiro A 3rd, Eisen S, **Sloan KL**, Rosen AK. Gender differences in veterans health administration mental health service use. *Womens Health Issues*. 19(3):176-84. May-Jun 2009.

### **BOOK CHAPTER:**

1. Ries RK, **Sloan KL** and Miller NS: Dual Diagnosis: Concept, Diagnosis, and Treatment. *Current Psychiatric Therapy*. 2nd ed. Dunner D, ed. Saunders 1997.

### **LETTERS AND OTHER PUBLICATIONS:**

1. **Sloan KL**, Haver VM and Saxon, AJ: Quetiapine and False-Positive Urine Drug Testing for Tricyclic Antidepressants [letter]. *Am J Psychiatry* 157(1):148-149, 2000.
2. Shores MM, **Sloan KL**: Phenytoin-induced visual disturbances misdiagnosed as alcohol withdrawal [letter]. *Psychosomatics* 43(4):335-6, 2002.

### **ABSTRACTS:**

1. **Sloan KL** and Rowe G: Substance Abuse and Psychiatric Illness: Psychosocial Correlates. Annual meeting of the American Psychiatric Association, May, 1994.
2. Donovan DM, Rosengren DB, Downey LM, Friese L, Brennen S, Cox G, and **Sloan KL**: Motivational Interventions to Enhance Treatment Entry Among Drug Abusers. Presented at the National Institute on Drug Abuse Conference, Treatment Readiness: Factors Influencing Entry and Engagement, Rockville, MD, December, 1996.

## CURRICULUM VITAE

**Kevin L. Sloan, M.D.**

**Page 8 of 11**

3. **Sloan KL**, Kivlahan DR and Saxon AJ: Screening for Bipolar Disorder Among Treatment-Seeking Substance Abusers. New Research Program and Abstracts, Annual meeting of the American Psychiatric Association, 136, 1998.
4. Saxon AJ, **Sloan KL**, Calsyn DA and Reoux JP: Screening for Attention Deficit Hyperactivity Disorder in substance-using patients with the Wender Utah Rating Scale. Problems of Drug Dependence 1998: Proceedings of the 60th Annual Scientific Meeting of the College on Problems of Drug Dependence, 52, 1999.
5. Reoux J, Malte C, Saxon A, **Sloan KL** and Baer J: Divalproex Sodium in Acute Alcohol Withdrawal. Alcoholism: Clinical and Experimental Research, 23(5):47A, 1999.
6. Saxon AJ, Davis TM, Fitzgibbons K, Baer JS, Kivlahan DR and **Sloan KL**: Smoking Cessation in an Outpatient Substance Dependence Treatment Clinic. Problems of Drug Dependence 1999: National Institute on Drug Abuse, NIH Pub. No. 00-4773, 203, 2000.
7. Sales AE, **Sloan KL** and Every NR: Cholesterol Screening for Primary Prevention: An effect of Computerized Reminders? VA HSR&D Eighteenth Annual Meeting, March 24, 2000.
8. **Sloan KL**, Sales AE, Every NR and Martin GV: Secondary Prevention of Ischemic Heart Disease – Guideline Concordance. *Oral presentation at the VA HSR&D Eighteenth Annual Meeting*, March 24, 2000.
9. **Sloan KL**, Sales AE, Fishman PA and Malkin JD: Comparing VA to the Group Health Population on the Chronic Disease Score Categories. *Oral presentation at the VA HSR&D Eighteenth Annual Meeting*, March 24, 2000.
10. Calsyn DA, DeMarco FJ, Saxon AJ, **Sloan KL** and Gibbon K: Evaluation of a “Minimal Services” Treatment Track as an Alternative to Discharge for Non-Compliant Patients in Opioid Substitution Treatment. Drug Alcohol Depend 60:S30, 2000.
11. **Sloan KL**, Sales AE, Liu CF, Fishman P, Sharp ND: Using the RxRisk as a Case-mix Descriptor – Test-Retest Reliability. *Oral presentation at the VA HSR&D Nineteenth Annual Meeting*, February 15, 2001.
12. Straits-Tröster KA, **Sloan KL**, Dominitz JA, and Kivlahan DR. Hepatitis C Virus (HCV) prevalence, access to care, and psychiatric co-morbidities in the Northwest Network. Proceedings of the VA HSR&D 19th Annual Meeting, 58-59, 2001.
13. Maynard, C, Kivlahan, D, **Sloan, KL**, Krupski, T, Saxon, A Utilization of Veterans Affairs Healthcare Services by Veterans Receiving Publicly Funded Substance Abuse Services in Washington State. Proceedings of the VA HSR&D 19<sup>th</sup> Annual Meeting, 54-55, 2001
14. Shores M, **Sloan K**, Birdsong L, Matsumoto A, Kivlahan D: The Lifetime Prevalence and Incidence of Depression in Older Hypogonadal Men. *Presented at the 14th Annual Meeting of the American Association for Geriatric Psychiatry*, 2001.
15. Straits-Tröster KA, Calsyn DA, **Sloan KL**, Dominitz JA, and Kivlahan DR: Hepatitis C is a New Challenge for Behavioral Medicine. Annals of Behavioral Medicine, 23 (supplement), S105, 2001.



## CURRICULUM VITAE

**Kevin L. Sloan, M.D.**

**Page 9 of 11**

16. DeMarco FJ, Calsyn DA, Saxon AJ, **Sloan KL**, and Gibbon KE: Alternatives to discharge: Two-year outcomes of a “Minimal Services” program for non-compliant opioid substitution clients. *Annals of Behavioral Medicine*, 23 (supplement), S153, 2001.
17. Saxon AJ, Calsyn DA, **Sloan KL**, Baer JS, Kivlahan DR, Felker BL, Nichol P, Paden GR DeMarco F: Primary Care Attendance of Substance Dependent Patients. *Drug Alcohol Depend* 63:Suppl 1, 558, 2001.
18. **Sloan KL**, Sales AE, Sun H, Pineros S, Rothendler J: Comparing process and outcomes measures in the evaluation of ischemic heart disease secondary prevention. Paper presentation, 2001 Abstract Book, Annual Meeting of the Academy for Health Services Research and Health Policy, June 12, 2001.
19. **Sloan KL**, Sales AE, Liu CF, Fishman P, Sharp ND: Comparing Diagnosis and Prescription Strategies in the Assessment of Population Disease Burden. Poster presentation, 2001 Abstract Book, Annual Meeting of the Academy for Health Services Research and Health Policy, June 12, 2001.
20. **Sloan KL**, Sales AE, Liu CF, Fishman P, Sharp ND: Using the RxRisk as a Case-mix Descriptor – Test-Retest Reliability. Poster presentation, 2001 Abstract Book, Annual Meeting of the Academy for Health Services Research and Health Policy, June 12, 2001.
21. Straits-Troster, KA, McFall, ME, **Sloan, KL**, Dominitz, JA, Kivlahan, DR: Is PTSD a risk factor for Hepatitis C infection? Proceedings of the 17<sup>th</sup> Annual Meeting of the International Society for Traumatic Stress Studies, New Orleans, LA, December, 2001.
22. **Sloan KL**, Liu CF, Sales AE, Fishman P, Todd-Stenberg J, Sharp ND, Rosen AK and Loveland S: Predicting Outpatient Pharmacy Cost using Diagnosis- and Pharmacy-Based Case-Mix Instruments. *Oral presentation at the VA HSR&D Nineteenth Annual Meeting*, February 14, 2002.
23. **Sloan KL**, Straits-Tröster KA, Dominitz JA and Kivlahan DR: Hepatitis C Testing in the VHA Northwest Network – Prevalence, Risk Markers & Future Recommendations. *Poster presentation at the VA HSR&D Nineteenth Annual Meeting*, February 14, 2002.
24. Ho PM, Starks H, Sun H, **Sloan KL**, Sales A, Maynard C: Adverse outcomes in ischemic heart disease patients who do not undergo a lipid measurement. *Oral presentation at the VA HSR&D Nineteenth Annual Meeting*, February 14, 2002.
25. Calsyn DA, Saxon AJ, Bush DN, Howell JS, Baer J, **Sloan KL**, Kivlahan DR: The SF-36V and the Addiction Severity Index tap similar constructs. *Drug and Alcohol Dependence*, 66, S25, 2002
26. Saxon AJ, **Sloan KL**, Nichol P, Howell JS, Bush DN, Calsyn DA, Baer J, Felker BL, Kivlahan DR: Substance-Dependent individuals often lack awareness of their medical conditions. *Drug and Alcohol Dependence*, 66, S156, 2002.
27. Chapko MK, **Sloan KL**, Davison J, Dufour DR, Bankson DD, Rigsby M, Dominitz JA: Evaluation of Hepatitis C Testing Strategies Using Decision Analysis. *Oral presentation at the VA HSR&D Twentieth National Meeting*, February 13, 2002.

## CURRICULUM VITAE

**Kevin L. Sloan, M.D.**

**Page 10 of 11**

28. Roberts LJ, Sloan KL, McKnight P, Beck B, Sweeney M, Lenert L, Kivlahan DR. Preferences for mental health outcomes among veterans with co-occurring schizophrenia and substance use disorder. *Oral presentation at the Association for Advancement of Behavior Therapy, Reno NV, November 2002.*
29. Straits-Tröster KA, Kivlahan DR, Bush K, Splan M, **Sloan KL**, Sporleder J, & Dominitz JA: Hepatitis C Virus (HCV) knowledge, health risk behaviors, and interest in health services among HCV+ veterans. *Annals of Behavioral Medicine, 25, S129. 2003.*
30. Dominitz JA, Straits-Tröster KA, Splan M, Bush K, **Sloan KL**, Lee SW, Kivlahan DR: Quality of life and impact of specialist care on knowledge and satisfaction among hepatitis C patients. *Oral presentation at Digestive Disease Week, May 2003.*
31. **Sloan KL**, Straits-Tröster KA, Kivlahan DR, Dominitz JA: Patterns in Hepatitis C: Prevalence and Comorbidities in Northwest Veterans. *Oral presentation at the Annual Meeting of the American Psychiatric Association, May 2003.*
32. Straits-Tröster KA, Dominitz JA, McFall ME, **Sloan KL**: PTSD and Hepatitis C Comorbidity and Implications for Interferon-Based Treatments. *Oral presentation at the Annual Meeting of the American Psychiatric Association, May 2003.*
33. Liu CF, Sales AE, **Sloan KL**, Sharp ND, Todd-Stenberg J, Fishman P, Nichol WP, Rosen AK, Loveland S: Comparing Pharmacy-Based And Diagnosis-Based Case Mix Adjustment Methods For Assessing Facility Performance. *Oral presentation at the Annual Meeting of the International Health Economics Association, June 2003.*
34. Zhou XHA, and **Sloan KL**: The impact of case-mix adjustment methodology on outlier identification: a case study profiling VA medical centers. *Oral presentation at the 2003 International Conference on Health Policy Research (ICHPR), October 2003.*
35. Dominitz JA, Straits-Troster KA, Splan MF, Bush KR, **Sloan KL**, Lee SW, Kivlahan DR. Impact of group education on knowledge, satisfaction and quality of life among hepatitis C patients seen by gastroenterologists. *Oral presentation at the 68th Annual Scientific Meeting - American College of Gastroenterology, Baltimore, MD, October 2003.*
36. **Sloan KL**, Rosen AK, Christiansen CL, Montez M. Low Density Lipoprotein in Ischemic Heart Disease Patients: Impact of Cut-Point on Facility Profiles. *Poster presentation at the VA HSR&D 2005 National Meeting, February 2005.*
37. **Sloan KL**, Fishman P, Burgess JF, Zhou XH, Zhou C. Risk adjustment for provider profiling – alternative models, additional considerations. *Oral presentation at the Annual Meeting of the International Health Economics Association, July 2005.*
38. Fishman P, **Sloan KL**, Burgess JF, Zhou XH, Zhou C. Issues in Evaluating Alternative Risk Assessment Models: Evidence from the US Veterans Population. *Oral presentation at the Annual Meeting of the International Health Economics Association, July 2005.*
39. **Sloan KL**, Burgess JF, Zhou C, Fishman P, Zhou XH, Wang, L. Model Selection vs. Information Selection for Performance Evaluation: Where Best to Invest? *Oral presentation at the biennial International Conference on Health Policy Research, October 2005.*

## CURRICULUM VITAE

**Kevin L. Sloan, M.D.**

**Page 11 of 11**

40. **Sloan KL**, Davison J, Chapko MK, Dominitz JA. Hepatitis C Seroconversion is Still Occurring in Veterans. *Poster presentation at the 2005 CDC National Viral Hepatitis Prevention Conference*. December 2005.
41. Chapko MK, **Sloan KL**, Davison J, Dominitz JA. Cost-Effectiveness of Testing Strategies for Chronic Hepatitis C. *Oral presentation at the 2005 CDC National Viral Hepatitis Prevention Conference*. December 2005.
42. Chapko MK, **Sloan KL**, Davison J, Dominitz JA. Viral hepatitis prevention for adults: delivering, implementing, and evaluating prevention and control strategies and services. *Poster presentation at the 2005 CDC National Viral Hepatitis Prevention Conference*. December 2005.
43. Rousseau CM, Ioannou GN, Todd-Stenberg JA, **Sloan KL**, Dominitz JA. Racial Differences in the Evaluation and Treatment of Hepatitis C: A Retrospective Cohort Study. *Oral presentation at the VA HSR&D 2006 National Meeting*, February 2006.
44. Kivlahan DR, Malte CA, Hawkins EJ, Baer JS, **Sloan KL**, Calsyn DA, Saxon AJ. Health Status Changes with Onsite vs. Referral Primary Care for Veterans in Addictions Treatment. *Plenary oral presentation at the VA HSR&D 2006 National Meeting*, February 2006.
45. **Sloan KL**, Burgess JF, Zhou C, Fishman P, Zhou XH, Wang, L. Where Best to Invest? Model Selection vs. Information Selection for Performance Evaluation: *Oral presentation at the VA HSR&D 2006 National Meeting*, February 2006.
46. **Sloan KL**, Burgess JF. Analyzing Health Care Cost Data in the Presence of Heterogeneous Patients: Wouldn't Three Pieces Be Better Than One? *Oral presentation at 2007 Joint Statistical Meeting*, August 2007.
47. Madaras-Kelly KJ, Remington RE, Fan VS, **Sloan KL**. The Etiology of Health Care-Associated Pneumonia (HCAP). *Poster presentation at 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy*.
48. Madaras-Kelly KJ, Remington RE, Fan VS, **Sloan KL**. How Often is a Microbial Etiology Identified in Health Care-Associated Pneumonia (HCAP)? *Poster presentation at 2009 Interscience Conference on Antimicrobial Agents and Chemotherapy*.